{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:44:05Z","timestamp":1782830645352,"version":"3.54.5"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03298-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:55:53Z","timestamp":1781258153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic vulnerabilities in advanced prostate cancer: the interplay of ferroptosis, cuproptosis, and the inflammatory microenvironment"],"prefix":"10.1007","volume":"43","author":[{"given":"Farzaneh","family":"Motafeghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossein Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Ghassemi Barghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"1","key":"3298_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75(1):88\u201399.","journal-title":"Eur Urol"},{"issue":"10","key":"3298_CR2","doi-asserted-by":"publisher","first-page":"a030569","DOI":"10.1101\/cshperspect.a030569","volume":"8","author":"G Zadra","year":"2018","unstructured":"Zadra G, Loda M. Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities. Cold Spring Harbor Perspect Med. 2018;8(10):a030569.","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"6","key":"3298_CR3","doi-asserted-by":"publisher","first-page":"a030635","DOI":"10.1101\/cshperspect.a030635","volume":"8","author":"S Sumanasuriya","year":"2018","unstructured":"Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer\u2014A review of current therapies and future promise. Cold Spring Harbor Perspect Med. 2018;8(6):a030635.","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"2","key":"3298_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/2159-8290.CD-20-0789","volume":"11","author":"E Koren","year":"2021","unstructured":"Koren E, Fuchs Y. Modes of regulated cell death in cancer. Cancer Discov. 2021;11(2):245\u201365.","journal-title":"Cancer Discov"},{"issue":"6586","key":"3298_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"issue":"4","key":"3298_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3298_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cancers16030512","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang J, Li J, Liu J, Chan K-Y, Lee H-S, Lin KN, et al. Interplay of ferroptosis and cuproptosis in cancer: dissecting metal-driven mechanisms for therapeutic potentials. Cancers. 2024;16(3):512.","journal-title":"Cancers"},{"key":"3298_CR8","doi-asserted-by":"publisher","first-page":"1650219","DOI":"10.3389\/fonc.2025.1650219","volume":"15","author":"W Gao","year":"2025","unstructured":"Gao W, Tan J, Yu C. Ferroptosis in the tumor microenvironment: mechanisms, advances, and therapeutic perspectives. Front Oncol. 2025;15:1650219.","journal-title":"Front Oncol"},{"key":"3298_CR9","doi-asserted-by":"publisher","first-page":"153373","DOI":"10.1016\/j.cej.2024.153373","volume":"495","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen G, You X, Wang X. Cuproptosis nanomedicine: clinical challenges and opportunities for anti-tumor therapy. Chem Eng J. 2024;495:153373.","journal-title":"Chem Eng J"},{"issue":"6","key":"3298_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu E-C, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81(6):1583\u201394.","journal-title":"Cancer Res"},{"issue":"19","key":"3298_CR11","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, Yan B, Li H, Ding D, Wang L, Pang J, et al. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res. 2023;83(19):3192\u2013204.","journal-title":"Cancer Res"},{"issue":"6","key":"3298_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.10.011","volume":"32","author":"J Zheng","year":"2020","unstructured":"Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metabol. 2020;32(6):920\u201337.","journal-title":"Cell Metabol"},{"issue":"14","key":"3298_CR13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401\u201321.","journal-title":"Cell"},{"issue":"3","key":"3298_CR14","doi-asserted-by":"publisher","first-page":"188890","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878(3):188890.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"5","key":"3298_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat reviews Clin Oncol. 2021;18(5):280\u201396.","journal-title":"Nat reviews Clin Oncol"},{"issue":"7784","key":"3298_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693\u20138.","journal-title":"Nature"},{"issue":"7860","key":"3298_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593(7860):586\u201390.","journal-title":"Nature"},{"issue":"1","key":"3298_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"VA Kraft","year":"2019","unstructured":"Kraft VA, Bezjian CT, Pfeiffer S, Ringelstetter L, M\u00fcller C, Zandkarimi F, et al. GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2019;6(1):41\u201353.","journal-title":"ACS Cent Sci"},{"issue":"4","key":"3298_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","volume":"1","author":"LC Harshman","year":"2015","unstructured":"Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1(4):495\u2013504.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3298_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273\u201385.","journal-title":"Cell"},{"issue":"7784","key":"3298_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688\u201392.","journal-title":"Nature"},{"issue":"12Supplement","key":"3298_CR22","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/1538-7445.AM2022-2166","volume":"82","author":"R Talty","year":"2022","unstructured":"Talty R, Ferreira M, Krykbaeva I, Bosenberg M. Ibuprofen induces ferroptosis to potentiate antitumor immunity. Cancer Res. 2022;82(12Supplement):2166.","journal-title":"Cancer Res"},{"key":"3298_CR23","doi-asserted-by":"publisher","first-page":"102426","DOI":"10.1016\/j.redox.2022.102426","volume":"55","author":"H Chen","year":"2022","unstructured":"Chen H, Qi Q, Wu N, Wang Y, Feng Q, Jin R, et al. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR\/SREBP-1\/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer. Redox Biol. 2022;55:102426.","journal-title":"Redox Biol"},{"issue":"2","key":"3298_CR24","first-page":"118893","volume":"1868","author":"VC Shanbhag","year":"2021","unstructured":"Shanbhag VC, Gudekar N, Jasmer K, Papageorgiou C, Singh K, Petris MJ. Copper metabolism as a unique vulnerability in cancer. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2021;1868(2):118893.","journal-title":"Cell Res"},{"issue":"1","key":"3298_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","volume":"7","author":"L Chen","year":"2022","unstructured":"Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target therapy. 2022;7(1):378.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"3298_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12943-023-01732-y","volume":"22","author":"J Xie","year":"2023","unstructured":"Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22(1):46.","journal-title":"Mol Cancer"},{"issue":"10","key":"3298_CR27","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.molcel.2022.05.001","volume":"82","author":"PA Cobine","year":"2022","unstructured":"Cobine PA, Brady DC, Cuproptosis. Cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell. 2022;82(10):1786\u20137.","journal-title":"Mol Cell"},{"issue":"4","key":"3298_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41585-020-0288-x","volume":"17","author":"DA Bader","year":"2020","unstructured":"Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Reviews Urol. 2020;17(4):214\u201331.","journal-title":"Nat Reviews Urol"},{"key":"3298_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fonc.2017.00131","volume":"7","author":"E Eidelman","year":"2017","unstructured":"Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The metabolic phenotype of prostate cancer. Front Oncol. 2017;7:131.","journal-title":"Front Oncol"},{"issue":"5","key":"3298_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417\u20138.","journal-title":"Cell Res"},{"issue":"2","key":"3298_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discovery. 2022;21(2):141\u201362.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"3298_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657\u201369.","journal-title":"Cell"},{"key":"3298_CR33","doi-asserted-by":"publisher","first-page":"116115","DOI":"10.1016\/j.biopha.2023.116115","volume":"171","author":"N Liu","year":"2024","unstructured":"Liu N, Chen M. Crosstalk between ferroptosis and cuproptosis: from mechanism to potential clinical application. Biomed Pharmacother. 2024;171:116115.","journal-title":"Biomed Pharmacother"},{"key":"3298_CR34","doi-asserted-by":"publisher","first-page":"1493188","DOI":"10.3389\/fphar.2024.1493188","volume":"15","author":"M Imam","year":"2025","unstructured":"Imam M, Ji J, Zhang Z, Yan S. Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application. Front Pharmacol. 2025;15:1493188.","journal-title":"Front Pharmacol"},{"key":"3298_CR35","doi-asserted-by":"crossref","unstructured":"Lu Y, Wu Y, Yang C, Zhou Y, Ren X, Li H et al. Ferredoxins: master regulators in mitochondrial redox homeostasis and programmed cell death. Redox Biol. 2025:103930. https:\/\/pubmed.ncbi.nlm.nih.gov\/41260099\/","DOI":"10.1016\/j.redox.2025.103930"},{"key":"3298_CR36","doi-asserted-by":"crossref","unstructured":"Chen Y, Liu Y, Huang J. Emodin Triggers Cuproptosis to Suppress Hepatocellular Carcinoma via SLC7A11\/FDX1 Axis. Front Oncol.16:1756712. 2026 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13056838\/","DOI":"10.3389\/fonc.2026.1756712"},{"issue":"12","key":"3298_CR37","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1002\/1878-0261.13079","volume":"15","author":"W Gao","year":"2021","unstructured":"Gao W, Huang Z, Duan J, Nice EC, Lin J, Huang C. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. Mol Oncol. 2021;15(12):3527\u201344.","journal-title":"Mol Oncol"},{"issue":"4","key":"3298_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/carcin\/bgad020","volume":"44","author":"AJ Bagherpoor","year":"2023","unstructured":"Bagherpoor AJ, Shameem M, Luo X, Seelig D, Kassie F. Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. Carcinogenesis. 2023;44(4):291\u2013303.","journal-title":"Carcinogenesis"},{"issue":"4","key":"3298_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2020.02.005","volume":"27","author":"J Liu","year":"2020","unstructured":"Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem biology. 2020;27(4):420\u201335.","journal-title":"Cell Chem biology"},{"issue":"4","key":"3298_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.20892\/j.issn.2095-3941.2019.0158","volume":"16","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Shen Y, Chen C, Sui X, Yang J, Wang L, et al. The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer? Cancer biology Med. 2019;16(4):630\u201346.","journal-title":"Cancer biology Med"},{"issue":"1","key":"3298_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12943-024-02130-8","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang X, Tang B, Luo J, Yang Y, Weng Q, Fang S, et al. Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope. Mol Cancer. 2024;23(1):255.","journal-title":"Mol Cancer"},{"key":"3298_CR42","doi-asserted-by":"crossref","unstructured":"Zhang D, Zhao Y, Guo D. Application and Potential of the Tumor Microenvironment, Ferroptosis, Cuproptosis, and Disulfidptosis in Cancer Treatment and Monitoring. Crit Rev Oncol\/Hematol. 2025:105066. https:\/\/pubmed.ncbi.nlm.nih.gov\/41352618\/","DOI":"10.1016\/j.critrevonc.2025.105066"},{"issue":"1","key":"3298_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-025-00880-1","volume":"14","author":"T Tong","year":"2026","unstructured":"Tong T, Guan Y, Luo J, Yan B, Yang X, Zhang J, et al. Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer. Biomark Res. 2026;14(1):6.","journal-title":"Biomark Res"},{"key":"3298_CR44","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.mam.2024.101280","volume":"98","author":"T Tong","year":"2024","unstructured":"Tong T, Huang M, Yan B, Lin B, Yu J, Teng Q, et al. Hippo signaling modulation and its biological implications in urological malignancies. Mol Aspects Med. 2024;98:101280.","journal-title":"Mol Aspects Med"},{"issue":"41","key":"3298_CR45","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1038\/s41388-025-03548-0","volume":"44","author":"T Tong","year":"2025","unstructured":"Tong T, Lei H, Huang M, Yang Z, Dai X, Zou H, et al. HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer. Oncogene. 2025;44(41):3895\u2013908.","journal-title":"Oncogene"},{"key":"3298_CR46","doi-asserted-by":"publisher","first-page":"810893","DOI":"10.3389\/fonc.2021.810893","volume":"11","author":"J Xu","year":"2022","unstructured":"Xu J, Liu X-Y, Zhang Q, Liu H, Zhang P, Tian Z-B, et al. Crosstalk among YAP, LncRNA, and tumor-associated macrophages in tumorigenesis development. Front Oncol. 2022;11:810893.","journal-title":"Front Oncol"},{"issue":"2","key":"3298_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","volume":"22","author":"EJ Ge","year":"2022","unstructured":"Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102\u201313.","journal-title":"Nat Rev Cancer"},{"key":"3298_CR48","doi-asserted-by":"publisher","first-page":"1697008","DOI":"10.3389\/fimmu.2025.1697008","volume":"16","author":"Q Yang","year":"2025","unstructured":"Yang Q, Yang Z, Zhao H. Lactylation in cancer: mechanistic insights, tumor microenvironment, and therapeutic horizons. Front Immunol. 2025;16:1697008.","journal-title":"Front Immunol"},{"issue":"1","key":"3298_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41419-025-07498-z","volume":"16","author":"J Deng","year":"2025","unstructured":"Deng J, Li Y, Yin L, Liu S, Li Y, Liao W, et al. Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. Cell Death Dis. 2025;16(1):193.","journal-title":"Cell Death Dis"},{"key":"3298_CR50","doi-asserted-by":"crossref","unstructured":"Wang Y, Chen J, Wang Y, Cao Y, Li Y, Zhu Y et al. Targeting Lactylation Offers Therapy to Reverse Cell Death Resistance. Drug Design, Development and Therapy. 2025:11371-94.","DOI":"10.2147\/DDDT.S567488"},{"issue":"1","key":"3298_CR51","doi-asserted-by":"publisher","first-page":"2952331","DOI":"10.1155\/mi\/2952331","volume":"2026","author":"Y Wang","year":"2026","unstructured":"Wang Y, Zhu Y, Wang Y, Liu Y, Wang P, Yu M. Cuproptosis at the Crossroads of Tumor Microenvironment Inflammation and Metabolic Rewiring Mechanisms and Therapeutic Opportunities. Mediat Inflamm. 2026;2026(1):2952331.","journal-title":"Mediat Inflamm"},{"issue":"9","key":"3298_CR52","doi-asserted-by":"publisher","first-page":"e70349","DOI":"10.1002\/mco2.70349","volume":"6","author":"G Shen","year":"2025","unstructured":"Shen G, Liu J, Wang Y, Deng Z, Deng F. Ferroptosis in cancer and inflammatory diseases: mechanisms and therapeutic implications. MedComm. 2025;6(9):e70349.","journal-title":"MedComm"},{"issue":"5","key":"3298_CR53","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.7150\/thno.123080","volume":"16","author":"M Wang","year":"2026","unstructured":"Wang M, Shi C, Shu Z, Li Z. Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy. Theranostics. 2026;16(5):2405.","journal-title":"Theranostics"},{"key":"3298_CR54","doi-asserted-by":"publisher","first-page":"1772259","DOI":"10.3389\/fimmu.2026.1772259","volume":"17","author":"Z Lv","year":"2026","unstructured":"Lv Z, Liu Z, Nie Z, Li N, Kong L, Shen F, et al. Ferroptosis reshapes the tumor immune microenvironment: molecular mechanisms, immune regulation, and therapeutic synergistic strategies. Front Immunol. 2026;17:1772259.","journal-title":"Front Immunol"},{"key":"3298_CR55","doi-asserted-by":"publisher","unstructured":"Cui PP, Yang QC, Sun ZJ. Targeting cuproptosis with nanomaterials for cancer immunotherapy. Acta Biomater. 2026 Jan;209:38-63. Epub 2025 Nov 19. PMID: 41271077.https:\/\/doi.org\/10.1016\/j.actbio.2025.11.028","DOI":"10.1016\/j.actbio.2025.11.028"},{"issue":"1","key":"3298_CR56","doi-asserted-by":"publisher","first-page":"e71519","DOI":"10.1002\/cam4.71519","volume":"15","author":"DE Uti","year":"2026","unstructured":"Uti DE, Omang WA, Alum EU, Bawa I, Ugwu OPC, Idowu AO, et al. Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia\u2010Inducible Factor\u20101 Alpha and Downstream Metabolites. Cancer Med. 2026;15(1):e71519.","journal-title":"Cancer Med"},{"issue":"12","key":"3298_CR57","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1021\/acsnano.3c12745","volume":"18","author":"Q Cheng","year":"2024","unstructured":"Cheng Q, Shi X, Chen Y, Li Q, Wang J, Li H, et al. Tumor microenvironment-activatable nanosystem capable of overcoming multiple therapeutic obstacles for augmenting immuno\/metal-ion therapy. ACS Nano. 2024;18(12):8996\u20139010.","journal-title":"ACS Nano"},{"issue":"3","key":"3298_CR58","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/15548627.2022.2103961","volume":"19","author":"S Chouhan","year":"2023","unstructured":"Chouhan S, Sawant M, Weimholt C, Luo J, Sprung RW, Terrado M, et al. TNK2\/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability. Autophagy. 2023;19(3):1000\u201325.","journal-title":"Autophagy"},{"key":"3298_CR59","doi-asserted-by":"publisher","unstructured":"Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a030569. PMID: 29229664; PMCID: PMC6169980. https:\/\/doi.org\/10.1101\/cshperspect.a030569","DOI":"10.1101\/cshperspect.a030569"},{"key":"3298_CR60","doi-asserted-by":"crossref","unstructured":"Chouhan S, Singh S, Athavale D, Ramteke P, Vanuopadath M, Nair BG, Nair SS, Bhat MK. Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucosedependent alterations in reactive oxygen species, P-glycoprotein and DKK4. J Biosci. 2020;45:97. PMID: 32713860.","DOI":"10.1007\/s12038-020-00065-y"},{"issue":"6657","key":"3298_CR61","doi-asserted-by":"publisher","first-page":"eabq4964","DOI":"10.1126\/science.abq4964","volume":"381","author":"D Bressan","year":"2023","unstructured":"Bressan D, Battistoni G, Hannon GJ. The dawn of spatial omics. Science. 2023;381(6657):eabq4964.","journal-title":"Science"},{"issue":"1","key":"3298_CR62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discovery. 2020;19(1):39\u201356.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"3298_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s43556-026-00416-5","volume":"7","author":"J Wang","year":"2026","unstructured":"Wang J, Guo D, Jiang S, Wu W, Gao X. Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches. Mol Biomed. 2026;7(1):20.","journal-title":"Mol Biomed"},{"key":"3298_CR64","doi-asserted-by":"publisher","first-page":"0094","DOI":"10.34133\/bmr.0094","volume":"28","author":"D Noh","year":"2024","unstructured":"Noh D, Lee H, Lee S, Sun I-C, Yoon HY. Copper-based nanomedicines for cuproptosis-mediated effective cancer treatment. Biomaterials Res. 2024;28:0094.","journal-title":"Biomaterials Res"},{"issue":"1","key":"3298_CR65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12967-025-06180-4","volume":"23","author":"H Yang","year":"2025","unstructured":"Yang H, Zhang X, Jia Z, Wang H, Wu J, Wei X, et al. Targeting ferroptosis in prostate cancer management: molecular mechanisms, multidisciplinary strategies and translational perspectives. J Translational Med. 2025;23(1):166.","journal-title":"J Translational Med"},{"key":"3298_CR66","doi-asserted-by":"crossref","unstructured":"Li, S., Wang, W., Kou, S., Ding, X., Jin, J., Yang, Z., & Hua, D. (2025). Promoting endogenous iron mediated ferroptosis for cancer therapy through gene interference and reactive oxygen species amplification. Journal of colloid and interface science, 707, 139717 .","DOI":"10.1016\/j.jcis.2025.139717"},{"issue":"1","key":"3298_CR67","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12951-024-02457-w","volume":"22","author":"J Yang","year":"2024","unstructured":"Yang J, Xiong W, Huang L, Li Z, Fan Q, Hu F, et al. A mesoporous superparamagnetic iron oxide nanoparticle as a generic drug delivery system for tumor ferroptosis therapy. J Nanobiotechnol. 2024;22(1):204.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3298_CR68","doi-asserted-by":"publisher","first-page":"tfad127","DOI":"10.1093\/toxres\/tfad127","volume":"13","author":"F Motafeghi","year":"2024","unstructured":"Motafeghi F, Mortazavi P, Shokrzadeh M. Anticancer activity of zinc oxide nanoparticles on prostate and colon cancer cell line. Toxicol Res. 2024;13(1):tfad127.","journal-title":"Toxicol Res"},{"issue":"3","key":"3298_CR69","doi-asserted-by":"publisher","first-page":"e2301345","DOI":"10.1002\/adhm.202301345","volume":"13","author":"Y Guan","year":"2024","unstructured":"Guan Y, Lei H, Xing C, Yan B, Lin B, Yang X, et al. Multimodal Nanoplatform with ROS Amplification to Overcome Multidrug Resistance in Prostate Cancer via Targeting P-Glycoprotein and Ferroptosis. Adv Healthc Mater. 2024;13(3):e2301345.","journal-title":"Adv Healthc Mater"},{"key":"3298_CR70","doi-asserted-by":"publisher","first-page":"103046","DOI":"10.1016\/j.copbio.2023.103046","volume":"85","author":"W-C Chou","year":"2024","unstructured":"Chou W-C, Lin Z. Impact of protein coronas on nanoparticle interactions with tissues and targeted delivery. Curr Opin Biotechnol. 2024;85:103046.","journal-title":"Curr Opin Biotechnol"},{"key":"3298_CR71","doi-asserted-by":"publisher","unstructured":"Chen L, Deng X, Shen Q, Chen M, Li C, Wang S. Novel Dual Strategy Based on EPR\/AT for Optimizing Therapeutic Effect by Improving Drug Delivery System Physicochemical Properties and Regulating TME. Int J Nanomedicine. 2026 Jan 15;21: 559763. PMID: 41858577; PMCID: PMC12998905.https:\/\/doi.org\/10.2147\/IJN.S559763","DOI":"10.2147\/IJN.S559763"},{"issue":"2","key":"3298_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/nnm-2022-0257","volume":"18","author":"P Gawali","year":"2023","unstructured":"Gawali P, Saraswat A, Bhide S, Gupta S, Patel K. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a \u2018golden gate\u2019for nanomedicine in preclinical studies? Nanomedicine. 2023;18(2):169\u201390.","journal-title":"Nanomedicine"},{"issue":"9","key":"3298_CR73","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","volume":"31","author":"SJ O\u2019Day","year":"2013","unstructured":"O\u2019Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3298_CR74","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/toxres\/tfad060","volume":"12","author":"F Motafeghi","year":"2023","unstructured":"Motafeghi F, Shahsavari R, Mortazavi P, Babaei A, Samadi Mojaveri P, Khojasteh OA, et al. Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action. Toxicol Res. 2023;12(4):702\u20138.","journal-title":"Toxicol Res"},{"issue":"48","key":"3298_CR75","doi-asserted-by":"publisher","first-page":"41118","DOI":"10.1021\/acsami.8b14940","volume":"10","author":"W Chen","year":"2018","unstructured":"Chen W, Yang W, Chen P, Huang Y, Li F. Disulfiram copper nanoparticles prepared with a stabilized metal ion ligand complex method for treating drug-resistant prostate cancers. ACS Appl Mater Interfaces. 2018;10(48):41118\u201328.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"12","key":"3298_CR76","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/biom14121651","volume":"14","author":"K Butcher","year":"2024","unstructured":"Butcher K, Wang Z, Kurusamy S, Zhang Z, Morris MR, Najlah M, et al. PLGA-nano-encapsulated disulfiram inhibits cancer stem cells and targets non-small cell lung cancer in vitro and in vivo. Biomolecules. 2024;14(12):1651.","journal-title":"Biomolecules"},{"issue":"11","key":"3298_CR77","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/pharmaceutics11110610","volume":"11","author":"M Najlah","year":"2019","unstructured":"Najlah M, Said Suliman A, Tolaymat I, Kurusamy S, Kannappan V, Elhissi AM, et al. Development of injectable PEGylated liposome encapsulating disulfiram for colorectal cancer treatment. Pharmaceutics. 2019;11(11):610.","journal-title":"Pharmaceutics"},{"issue":"23","key":"3298_CR78","doi-asserted-by":"publisher","first-page":"11651","DOI":"10.3390\/ijms262311651","volume":"26","author":"H Talebian","year":"2025","unstructured":"Talebian H, Ait-Mohand S, Ignatius Arokia Doss PM, Sanche L, Gu\u00e9rin B. Development and In Vitro Evaluation of [64Cu] Cu-NOTA-TP-PSMA, a Novel Radiotheranostic Agent Against Prostate Cancer. Int J Mol Sci. 2025;26(23):11651.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3298_CR79","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11864-025-01317-5","volume":"26","author":"A Ayzman","year":"2025","unstructured":"Ayzman A, Pachynski RK, Reimers MA. PSMA-based therapies and novel therapies in advanced prostate cancer: The now and the future. Curr Treat Options Oncol. 2025;26(5):375\u201384.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"3298_CR80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Reviews Urol. 2025;22(1):26\u201345.","journal-title":"Nat Reviews Urol"},{"issue":"5","key":"3298_CR81","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3892\/ol.2024.14659","volume":"28","author":"Z Yu","year":"2024","unstructured":"Yu Z, Deng H, Chao H, Song Z, Zeng T. Construction of a cuproptosis\u2013related lncRNA signature to predict biochemical recurrence of prostate cancer. Oncol Lett. 2024;28(5):526.","journal-title":"Oncol Lett"},{"issue":"1","key":"3298_CR82","doi-asserted-by":"publisher","first-page":"20230717","DOI":"10.1515\/med-2023-0717","volume":"18","author":"X Wang Xa, Chen","year":"2023","unstructured":"Wang Xa, Chen X, Xu C, Zhou W, Wu D. Identification of cuproptosis-related genes for predicting the development of prostate cancer. Open Med. 2023;18(1):20230717.","journal-title":"Open Med"},{"issue":"3","key":"3298_CR83","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/cancers18030389","volume":"18","author":"J Robaczy\u0144ska","year":"2026","unstructured":"Robaczy\u0144ska J, Maj M, Kilja\u0144czyk A, Pastuszek B, Reducha E, Nurkiewicz A, et al. Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation. Cancers. 2026;18(3):389.","journal-title":"Cancers"},{"issue":"11","key":"3298_CR84","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3390\/life15111719","volume":"15","author":"V Pecci","year":"2025","unstructured":"Pecci V, Borsa M, Aiello A, De Martino S, Cis L, Pierconti F, et al. A Feasibility Study of Co-Established Patient-Derived Subcutaneous Xenograft and Organotypic Slice Cultures in Hormone-Naive Primary Prostate Cancer Preclinical Modeling: A Single-Institution Experience. Life. 2025;15(11):1719.","journal-title":"Life"},{"key":"3298_CR85","doi-asserted-by":"publisher","first-page":"1659869","DOI":"10.3389\/fonc.2026.1659869","volume":"16","author":"Z Zhou","year":"2026","unstructured":"Zhou Z, Lao Y, Zhao K, Cheng L, Xiao X, Li W, et al. Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy. Front Oncol. 2026;16:1659869.","journal-title":"Front Oncol"},{"key":"3298_CR86","doi-asserted-by":"publisher","unstructured":"Motafeghi F, Ramezani Tehrani F, Ghassemi Barghi N. The iron-ferroptosis axis in bone homeostasis: a potential complementary pathway for osteoporosis in endometriosis. Eur J Med Res. 2026 Jan 19;31(1):372. PMID: 41555407; PMCID: PMC12955137.https:\/\/doi.org\/10.1016\/j.actbio.2025.11.028","DOI":"10.1016\/j.actbio.2025.11.028"},{"issue":"12","key":"3298_CR87","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.trecan.2023.08.004","volume":"9","author":"M Toninelli","year":"2023","unstructured":"Toninelli M, Rossetti G, Pagani M. Charting the tumor microenvironment with spatial profiling technologies. Trends Cancer. 2023;9(12):1085\u201396.","journal-title":"Trends Cancer"},{"issue":"10","key":"3298_CR88","doi-asserted-by":"publisher","first-page":"eadd8539","DOI":"10.1126\/sciadv.add8539","volume":"9","author":"F Zeng","year":"2023","unstructured":"Zeng F, Nijiati S, Liu Y, Yang Q, Liu X, Zhang Q, et al. Ferroptosis MRI for early detection of anticancer drug\u2013induced acute cardiac\/kidney injuries. Sci Adv. 2023;9(10):eadd8539.","journal-title":"Sci Adv"},{"issue":"2","key":"3298_CR89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ijo.2025.5828","volume":"68","author":"Y Huang","year":"2025","unstructured":"Huang Y, Mao J, Li X. Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers. Int J Oncol. 2025;68(2):15.","journal-title":"Int J Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03298-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03298-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03298-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:48:50Z","timestamp":1782827330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03298-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":89,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3298"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03298-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to participate, and consent to publish declarations"}},{"value":"The authors used Grammarly and Gemini for editorial assistance, grammatical refinement, and textsummarization to improve the readability of this manuscript. Figures were created using BioRender. All AI-assisted content was carefullyreviewed and verified by the authors, who assume full responsibility for the accuracy and integrity of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI Disclosure"}}],"article-number":"192"}}